20.08.2021 05:00:34
|
Alex Gorsky To Step Down As J&J's CEO And Joaquin Duato To Take Over CEO Role
(RTTNews) - Johnson & Johnson said that its vice chairman, Joaquin Duato, will become chief executive officer of the company on 3rd January 2022, with Chairman and chief executive officer Alex Gorsky transitioning to executive chairman.
Duato will also be appointed as a member of the company's board of directors.
"The decision to step aside was one of the most difficult of my career. This is the right time for the Company as our organization is delivering strong performance across all three segments and is positioned for continued success...," said Gorsky.
Gorsky has been serving as Chairman and Chief Executive Officer of Johnson & Johnson since 2012.
Duato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He is a past chair of PhRMA, and sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences and the Hess Corporation.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
01.01.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: Hätte sich eine Kapitalanlage in Johnson Johnson von vor 5 Jahren rentiert? (finanzen.at) | |
31.12.24 |
Minuszeichen in New York: Dow Jones zum Handelsende leichter (finanzen.at) | |
31.12.24 |
Handel in New York: Dow Jones legt am Nachmittag den Rückwärtsgang ein (finanzen.at) | |
31.12.24 |
Dow Jones-Handel aktuell: Dow Jones zum Start des Dienstagshandels mit Zuschlägen (finanzen.at) | |
30.12.24 |
Montagshandel in New York: Dow Jones legt nachmittags den Rückwärtsgang ein (finanzen.at) | |
30.12.24 |
Dow Jones-Handel aktuell: Dow Jones startet im Minus (finanzen.at) | |
27.12.24 |
Angespannte Stimmung in New York: So entwickelt sich der Dow Jones nachmittags (finanzen.at) | |
27.12.24 |
Zurückhaltung in New York: Das macht der Dow Jones aktuell (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 137,82 | -1,50% |